Investing Profile

Ed Mathers

VCInvestor

Partner at New Enterprise Associates (NEA)

nea.com/team/ed-mathersMaryland

Your Intro Paths to Ed Mathers

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →

Networks Ed is a member of

New Enterprise Associates (NEA) Network

43 CONNECTIONS

New Enterprise Associates Network

16 CONNECTIONS

Find Ed Mathers on

cb

Current Investing Position

New Enterprise Associates (NEA) Partner

Investment Range

$2.0M - $50.0M

Sweet Spot

$25.0M

Investments On Record

48

Current Fund Size

$6.2B

Ed Mathers is on these Sector & Stage Rankings

Health IT (Series B)Health IT (Series A)BioTech (Series B)Health & Hospital Services (Series A)Pharmaceuticals (Series A)Health & Hospital Services (Series B)Pharmaceuticals (Series B)BioTech (Series A)Pharmaceuticals (Series B)Pharmaceuticals (Series A)Health & Hospital Services (Series B)Health & Hospital Services (Series A)BioTech (Series B)Health IT (Series B)BioTech (Series A)Health IT (Series A)Washington, D.C.

Ed Mathers's Investments On Record (24)

Company	StageDateRound Size	Total Raised
MBX Biosciences	Series BNov 2022$120M Series AJul 2020$35M	$150M
Co-investors: Carl Gordon (OrbiMed), Patrick Heron (Frazier Healthcare Partners)
Inversago Pharma	Series COct 2022$69M	$110M
Co-investors: Elizabeth Douville (Amorchem), Marco Boorsma (Forbion), Nanna Luneborg (Forbion)
Code Biotherapeutics	Series AJun 2022$75M SeedApr 2021$10M	$85M
Co-investors: Victor Stone (Takeda Ventures), Diana Bernstein (Northpond Ventures), Dima Kuzmin (4BIO Capital)
Sentry	Series EMay 2022$90M Series DFeb 2021$60M Series CSep 2019$40M	$220M
Co-investors: Daniel Levine (Accel), Chetan Puttagunta (Benchmark), Jay Simons (Bond), Ilya Sukhar (Matrix)
Trevi Therapeutics	Post Ipo EquityApr 2022$55M Series CJan 2019$10M Series CAug 2018$11M Series CJul 2017$30M	$110M
Splice Bio	Series AFeb 2022$57M	$57M
Co-investors: Sylvain Sachot (Asabys Partners), Joël Jean-Mairet (Ysios Capital), Beat Steffen (Novartis Venture Fund)
Affinia Therapeutics	Series BMay 2021$110M Series AMar 2020$60M	$170M
Co-investors: Robert Weisskoff (F-Prime Capital Partners), David Grayzel (Atlas Venture)
Amplyx Pharmaceuticals	Series CMay 2020$53M Series CAug 2017$67M Series BNov 2015$41M	$160M
Co-investors: Niall O’Donnell (RiverVest), Alex Kahn (Generation Ventures)

Ed Mathers's Experience

Partner New Enterprise Associates (NEA)Present

Partner New Enterprise Associates2008 - Present

Ed Mathers's Education

NC State University Bachelor of Science (BS)